Article · 24 Feb 2026
Conference abstractPublished 24 Feb 2025
Prophylaxis with anticoagulants or antiplatelets: A randomized clinical trial in patients undergoing mitral valve repair and coronary artery bypass graft surgery
Babol University of Medical Sciences, Iran
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Challenges in adjusting the dosage of warfarin and the risk of bleeding complications due to its toxicity have drawn attention to antiplatelet agents as an alternative treatment for preventing thrombotic events in patients who require anticoagulation. This study aims to compare the effectiveness of oral anticoagulants (warfarin) and antiplatelet agents (Plavix) in patients who have undergone mitral valve repair plus Coronary Artery Bypass Grafting. Method: This randomized clinical trial was conducted on patients with ischemic mitral valve regurgitation who were candidates for coronary artery bypass grafting (CABG) and mitral valve (MV) repair at Ayatollah Rouhani Hospital in Babol. A total of 100 patients were included, with 50 assigned to the antiplatelet group (Plavix) and 50 to the anticoagulant group (warfarin). Patients were monitored for three months. The collected data were entered into SPSS software for analysis. Result: The mean age of patients in the warfarin group was 65.1 ± 8.2 years, with 24 (48%) being male and 26 (52%) female. In the Plavix group, the mean age was 63.3 ± 7.9 years, with 35 (70%) female and 15 (30%) male. Among patients receiving warfarin, 5 (10%) had an INR above 6. Of these, two remained asymptomatic, while three developed hemorrhagic complications. One of these patients suffered a hemorrhagic stroke, which resulted in death. However, no thromboembolic complications were observed in the warfarin group. In contrast, no thromboembolic or hemorrhagic complications were reported in patients receiving Plavix. Conclusion: The results of this study suggest that in patients undergoing mitral valve repair, Plavix is associated with fewer hemorrhagic and thromboembolic complications compared to warfarin. Therefore, Plavix may be considered a suitable alternative to warfarin in this patient population.
Subjects
Computer Science & ITAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Health & Medical Informatics.
Article · 24 Feb 2026
Authentication of Pharmaceutical Products in the Digital Marketplace: A Scoping Review
Commentary · 29 Nov 2025
Predictive Analytics: Optimizing Healthcare Operations For Better Outcomes
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Health & Medical Informatics
- SubjectComputer Science & IT
- BylineArticles whose byline prints “Zahra Mahjour”
- BylineArticles whose byline prints “Gh. Faghanzadeh Ganji”
- BylineArticles whose byline prints “A. Bijani”
